Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

High incidence of false-positive PET scans in patients with aggressive non-Hodgkin's lymphoma treated with rituximab-containing regimens.

Han HS, Escalón MP, Hsiao B, Serafini A, Lossos IS.

Ann Oncol. 2009 Feb;20(2):309-18. doi: 10.1093/annonc/mdn629. Epub 2008 Oct 7.

2.

Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET.

Halasz LM, Jacene HA, Catalano PJ, Van den Abbeele AD, Lacasce A, Mauch PM, Ng AK.

Int J Radiat Oncol Biol Phys. 2012 Aug 1;83(5):e647-54. doi: 10.1016/j.ijrobp.2012.01.060. Epub 2012 May 18.

PMID:
22607911
3.

Predictive value of (18)F-FDG hybrid PET/CT for the clinical outcome in patients with non-Hodgkin's lymphoma prior to and after autologous stem cell transplantation.

Qiao W, Zhao J, Wang C, Wang T, Xing Y.

Hematology. 2010 Feb;15(1):21-7. doi: 10.1179/102453310X12583347009739.

PMID:
20132658
4.

Midtreatment 18F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma.

Zinzani PL, Gandolfi L, Broccoli A, Argnani L, Fanti S, Pellegrini C, Stefoni V, Derenzini E, Quirini F, Baccarani M.

Cancer. 2011 Mar 1;117(5):1010-8. doi: 10.1002/cncr.25579. Epub 2010 Oct 19.

5.

Response-adapted therapy for aggressive non-Hodgkin's lymphomas based on early [18F] FDG-PET scanning: ECOG-ACRIN Cancer Research Group study (E3404).

Swinnen LJ, Li H, Quon A, Gascoyne R, Hong F, Ranheim EA, Habermann TM, Kahl BS, Horning SJ, Advani RH.

Br J Haematol. 2015 Jul;170(1):56-65. doi: 10.1111/bjh.13389. Epub 2015 Mar 30.

6.

False-positive FDG-PET findings due to bone metastasis from prostate cancer in staging of non-Hodgkin's lymphoma.

Inoue Y, Tamaki H, Yamagami T, Iwasaki H, Nakatsuka S, Soma T.

Eur J Haematol. 2007 Jul;79(1):88-90. Epub 2007 May 28. No abstract available.

PMID:
17532762
7.

The impact of R-VACOP-B and interim FDG-PET/CT on outcome in primary mediastinal large B cell lymphoma.

Avigdor A, Sirotkin T, Kedmi M, Ribakovsy E, Berkowicz M, Davidovitz Y, Kneller A, Merkel D, Volchek Y, Davidson T, Goshen E, Apter S, Shimoni A, Ben-Bassat I, Nagler A.

Ann Hematol. 2014 Aug;93(8):1297-304. doi: 10.1007/s00277-014-2043-y. Epub 2014 Mar 5.

PMID:
24595734
8.

Strikingly high false positivity of surveillance FDG-PET/CT scanning among patients with diffuse large cell lymphoma in the rituximab era.

Avivi I, Zilberlicht A, Dann EJ, Leiba R, Faibish T, Rowe JM, Bar-Shalom R.

Am J Hematol. 2013 May;88(5):400-5. doi: 10.1002/ajh.23423. Epub 2013 Mar 19.

9.

Response assessment after an inductive CHOP or CHOP-like regimen with or without rituximab in 103 patients with diffuse large B-cell lymphoma: integrating 18fluorodeoxyglucose positron emission tomography to the International Workshop Criteria.

Dupuis J, Itti E, Rahmouni A, Hemery F, Gisselbrecht C, Lin C, Copie-Bergman C, Belhadj K, El Gnaoui T, Gaillard I, Kuhnowski F, Meignan M, Haioun C.

Ann Oncol. 2009 Mar;20(3):503-7. doi: 10.1093/annonc/mdn671. Epub 2008 Dec 11.

PMID:
19074215
10.

Value of surveillance studies for patients with stage I to II diffuse large B-cell lymphoma in the rituximab era.

Hiniker SM, Pollom EL, Khodadoust MS, Kozak MM, Xu G, Quon A, Advani RH, Hoppe RT.

Int J Radiat Oncol Biol Phys. 2015 May 1;92(1):99-106. doi: 10.1016/j.ijrobp.2015.01.039.

PMID:
25863757
11.

[Non-pegylated liposomal doxorubicin in combination with cyclophosphamide, vincristine, prednisone and rituximab for the treatment of non-Hodgkin's lymphoma: study of 26 patients].

Moreno M, Sancho JM, Gardella S, Coll R, García O, Gallardo D, Ribera JM.

Med Clin (Barc). 2010 Jan 30;134(2):72-5. doi: 10.1016/j.medcli.2009.05.042. Epub 2009 Nov 12. Spanish.

PMID:
19913261
12.

Use of interim [18F]fluorodeoxyglucose-positron emission tomography is not justified in diffuse large B-cell lymphoma during first-line immunochemotherapy.

Cox MC, Ambrogi V, Lanni V, Cavalieri E, Pelliccia S, Scopinaro F, Monarca B, Marchetti P, Spiriti MA.

Leuk Lymphoma. 2012 Feb;53(2):263-9. doi: 10.3109/10428194.2011.614704. Epub 2011 Sep 23.

PMID:
21846184
13.

[Application of 18F-FDG PET for the assessment of early response to the treatment and prognosis of patients].

Oriuchi N, Higuchi T, Endo K, Tsukamoto N, Matsuda H, Kuji I, Murakami K, Nakajima K.

Kaku Igaku. 2009 Jun;46(2):96-9. Japanese.

PMID:
19637820
14.

Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants.

Trotman J, Fournier M, Lamy T, Seymour JF, Sonet A, Janikova A, Shpilberg O, Gyan E, Tilly H, Estell J, Forsyth C, Decaudin D, Fabiani B, Gabarre J, Salles B, Van Den Neste E, Canioni D, Garin E, Fulham M, Vander Borght T, Salles G.

J Clin Oncol. 2011 Aug 10;29(23):3194-200. doi: 10.1200/JCO.2011.35.0736. Epub 2011 Jul 11.

PMID:
21747087
15.

Impact of [(18)F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Groupe d'Etudes des Lymphomes de l'Adulte and GOELAMS.

Dupuis J, Berriolo-Riedinger A, Julian A, Brice P, Tychyj-Pinel C, Tilly H, Mounier N, Gallamini A, Feugier P, Soubeyran P, Colombat P, Laurent G, Berenger N, Casasnovas RO, Vera P, Paone G, Xerri L, Salles G, Haioun C, Meignan M.

J Clin Oncol. 2012 Dec 10;30(35):4317-22. doi: 10.1200/JCO.2012.43.0934. Epub 2012 Oct 29.

PMID:
23109699
16.

18F-FDG PET/CT for early response assessment in diffuse large B-cell lymphoma: poor predictive value of international harmonization project interpretation.

Cashen AF, Dehdashti F, Luo J, Homb A, Siegel BA, Bartlett NL.

J Nucl Med. 2011 Mar;52(3):386-92. doi: 10.2967/jnumed.110.082586. Epub 2011 Feb 14.

17.

[An update on recent developments in non-Hodgkin's lymphoma].

Bouabdallah K, Milpied N.

Bull Cancer. 2007 Jan;94(1):43-52. Review. French.

18.

[Therapeutic management of central nervous system lymphomas in a single hematological institute].

Iványi JL, Marton E, Plander M, Gyánó G, Czumbil L, Tóth C.

Orv Hetil. 2009 Oct 18;150(42):1937-44. doi: 10.1556/OH.2009.28703. Hungarian.

PMID:
19812012
19.

The therapeutic use of rituximab in non-Hodgkin's lymphoma.

Marcus R, Hagenbeek A.

Eur J Haematol Suppl. 2007 Jan;(67):5-14. Review.

PMID:
17206982
20.

[Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].

Huang HQ, Bu Q, Xia ZJ, Lin XB, Wang FH, Li YH, Peng YL, Pan ZH, Wang SS, Lin TY, Jiang WQ, Guan ZZ.

Ai Zheng. 2006 Apr;25(4):486-9. Chinese.

PMID:
16613686

Supplemental Content

Support Center